Galderma announced it has signed a memorandum of understanding with L’Oréal for a new R&D collaboration. L’Oréal will acquire a 10% stake in Galderma, recognising its leadership in dermatology and long-term growth potential. The partnership aims to accelerate innovation in dermatology through complementary research projects, enhancing both companies’ product portfolios.
Galderma’s CEO, Flemming Ørnskov, expressed excitement about the partnership, seeing L’Oréal’s investment as a sign of confidence in Galderma’s strategy and growth potential.
“We are on a journey of growth, innovation and leadership in the field of dermatology, powered by our unique integrated model,” he said. As we continue to deliver outstanding performance across our blockbuster platforms in attractive dermatology market segments, our commitment to progressing our current late-stage pipeline and advancing science and innovation remain a cornerstone of our approach. We are delighted to welcome L’Oréal as a new, long-term Galderma shareholder and see their investment as a sign of confidence in our strategy, track record and growth potential. We look forward to pursuing scientific partnership opportunities together, for the benefit of the customers, patients and consumers we serve across the globe every day.”
Nicolas Hieronimus, CEO of L’Oréal, highlighted this partnership as a significant step into the fast-growing aesthetics market.
“I am very pleased to announce this strategic investment and partnership with Galderma,” he said. “It marks an ambitious step for L’Oréal, and true to our mantra of ‘seize what is starting,’ it allows us to explore partnering in the fast-growing aesthetics market, a key adjacency to our own pure beauty play. We fully support Galderma’s management and its strategy as a leading dermatology pure player, respect its independence and are very confident in its long-term growth potential.”
L’Oréal’s investment comes with a commitment to support Galderma’s outstanding growth and maintain high ethical and environmental standards.
The transaction involves the sale of a 10% stake in Galderma Group AG by Sunshine SwissCo AG, Abu Dhabi Investment Authority, and Auba Investment Pte. Ltd. to L’Oréal. No changes to Galderma’s Board of Directors and governance are planned following the transaction.
Michael Bauer, Partner and Co-Head of Global Healthcare Sector at EQT, highlighted the strategic alignment with L’Oréal and commitment to Galderma’s growth in the dermatology market.
Galderma, founded in 1981, is a leader in dermatology, present in 90 countries, and focuses on Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. The company continues to invest in R&D, driving innovation and maintaining its growth-focused strategy.
Read the current issue of our digital magazine below:
- For more news and updates, subscribe to our weekly newsletter
- Follow us on Instagram
- Like us on Facebook
- Connect with us on LinkedIn